Delcath Systems, Inc. (NASDAQ:DCTH) has reported that the medicinal drug, Melphalan/HDS, which is responsible for the treatment of Unresectable Metastatic Ocular Melanoma has been accepted for presentation.
The study in question, which has been accepted for oral presentation, is under the title of “Percutaneous Hepatic Perfusion For Unresectable Metastatic Ocular Melanoma To The Liver: A Multi: Institutional Report Of Outcomes.”
More details about the study commenced using Melphalan/HDS
Allegedly, according to those who are familiar with the matter, the study itself was conducted by teams, which were situated at Moffitt Cancer Centre, which is based in Tampa, Florida. However, there were also teams working on said medicine, who were based at the University Of Southampton, in the United Kingdom.
The main cause of the study was to monitor patients results when implementing the medicinal treatment, in order to diagnose the effectiveness of this drug in the treatment of Unresectable Metastatic Ocular Melanoma.
The tests were commenced over a long duration of time, namely between the periods of 2008, to 2016. Although there was a vast number of people, actively involved in the project, the project lead was Dr Alexandra Gangi, who works out the Moffitt Cancer Centre.
More details about the oral presentation on the results from Melphalan/HDS
The party responsible for accepting the request of an oral presentation, regarding the results of the application of this medicine, in the treatment phase, is organisers at the Regional Cancer Therapies 12th International Symposium.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
This event will be taking place between the 18 to the 20, February. The location, at which this summit will take place, is the Snowboard Ski And Summer Resort, located in Snowbird, Utah. Various experts on the matter, have declared that they are looking forward to seeing the results obtained by this treatment, in hope to drive innovation towards more cures, and solutions as high as possible.
Delcath stock closed on Wednesday at $0,41, after falling by $0.06 or 11.96%
